Mckesson Corporation
Q2 2026 Earnings
Market Reaction
S&P 500 over the same 30 days: +1.90%.
Did MCK Beat Earnings? Q2 2026 Results
McKesson posted a decisive earnings beat in fiscal Q2 2026, with adjusted EPS of $9.86 clearing the $9.05 consensus estimate by 8.94%, even as revenue of $103.15 billion came in just under the $104.12 billion Wall Street had anticipated, a modest 0.93% shortfall. The top line still grew 10.1% year over year, reflecting broad-based momentum across the company's core businesses. The standout driver was the Oncology and Multispecialty segment, where revenues surged 32% to $12.04 billion and adjusted operating profit climbed 71% to $397 million, fueled by provider and specialty distribution growth, acquisition contributions, and net gains within The US Oncology Network. The North American Pharmaceutical segment, McKesson's largest at $86.48 billion in revenue, added further weight with adjusted operating profit rising 13% on specialty product tailwinds. Morgan Stanley raised its price target to $916 following the results, maintaining an Overweight rating. Looking ahead, McKesson lifted its full-year adjusted EPS guidance by $0.30 to a range of $38.35 to $38.85, implying 16% to 18% growth versus the prior year.
- Increased prescription transaction volumes from retail national account customers
- Growth in distribution of specialty products to health systems
- Impact of new product launches in pharmaceutical distribution
- Contributions from acquisitions in Oncology & Multispecialty segment
- Net gains from sale of an investment and market decisions within The US Oncology Network
- Higher demand for access solutions in Prescription Technology Solutions
- Lower tax rate contributing to adjusted EPS growth
- Operational efficiencies from cost optimization initiatives in Medical-Surgical
“McKesson's second quarter results underscore the strength of our differentiated assets, capabilities, and continued momentum as a diversified healthcare services leader. We delivered record revenue in the quarter of $103 billion, increasing 10% and Adjusted Earnings per Diluted Share accelerating 39% compared to the prior year. These results reflect disciplined execution of our enterprise strategy - advancing growth in oncology and multispecialty and biopharma services. We remain confident in our ability to create value for our customers, partners, employees, and shareholders.”
McKesson CEO, on the earnings call
Forward Guidance & Outlook
McKesson raised its fiscal 2026 full-year Adjusted Earnings per Diluted Share guidance by $0.30 to a range of $38.35 to $38.85, up from the prior range of $38.05 to $38.55. This builds on the $0.80 increase announced at Investor Day in September 2025. The updated guidance range indicates 16% to 18% growth compared to the prior year. The company does not provide forward-looking guidance on a GAAP basis.
MCK YoY Financials
MCK Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.